NEW YORK, Jan. 25, 2018 /PRNewswire/ -- Neurotrope, Inc.
(NASDAQ: NTRP), a clinical-stage biopharmaceutical company
developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease (AD), today announced that Dr.
Daniel Alkon, President and CSO,
will provide a corporate overview at the NobleCon 14th
Annual Institutional Investor Conference to be held at the W Hotel
in Fort Lauderdale, FL from
January 29th –
30th, 2018.
Neurotrope's corporate presentation will take place on
Tuesday, January 30th at
8:30 AM EST in Studio 2.
Dr. Alkon will also participate in a panel discussion entitled
"Central Nervous System: Is there a cure for Alzheimer's on the
Horizon?" on Monday, January
29th at 9:00 AM EST
in Studio 1 of the W Hotel.
A video webcast of Neurotrope's presentation will be available
here and on the Company's web site at
www.neurotropebioscience.com. The video webcast will be archived on
Neurotrope's website following the event.
About Bryostatin
Bryostatin-1 is a protein kinase C epsilon (PKCɛ) activator that
works through synaptic growth factors, as well as anti-amyloid and
anti-tangle signaling pathways in the brain. It has been shown in
preclinical efficacy studies to induce the growth of mature
synapses in the brain and prevent neuronal death. Thus,
Bryostatin-1 introduces a fundamentally different biological
mechanism of action with the potential for longer lasting effects
than the other currently available therapies. Bryostatin-1 is the
first PKCε modulator to be tested in a phase 2 clinical study
for patients suffering from moderate to severe AD — a difficult to
treat population.
The rationale for researching this novel mechanism in AD results
from in vitro and in vivo models of AD demonstrating
that modulation of PKCε by Bryostatin-1 enhances synaptogenesis and
prevents neuronal death. As synaptic loss is tightly
correlated with cognitive impairment in AD, this attribute of the
molecule made bryostatin an intriguing candidate for additional
investigation in dementia. Furthermore, preclinical studies also
demonstrated bryostatin reduces toxic Aß levels, prevents plaque
formation, inhibits tau phosphorylation, and enhances
cognition. Thus, the multimodal effects of this first PKCε
modulator offer a potential new mechanism to study in AD with the
ultimate goal to slow or prevent the progression of
disease.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combatting AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of bryostatin-1 in
moderate to severe AD, Neurotrope has also conducted preclinical
studies of bryostatin as a potential treatment for Fragile X
Syndrome, Niemann-Pick Type C disease and Rett Syndrome—three rare
genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for Bryostatin-1 as a treatment for Fragile X
Syndrome. Bryostatin-1 has already undergone testing in more
than 1,500 people in cancer studies, thus creating a large safety
data base that will further inform clinical trial designs in
AD.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical trial
data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year ended
December 31, 2016 and on Form 10-Q
for the quarter ending September 30,
2017. The Company does not undertake to update these
forward-looking statements.
Please visit www.neurotropebioscience.com for further
information.
Contact information:
Investors
Jeffrey Benison
Director of Corporate Communications
Neurotrope Bioscience, Inc.
516.286.6099
jbenison@neurotropebioscience.com
Media
James Heins
Senior Vice President
ICR Healthcare
203.856.2121
james.heins@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-at-noblecon-14th-annual-institutional-investor-conference-300588070.html
SOURCE Neurotrope, Inc.